201 related articles for article (PubMed ID: 34507591)
1. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Morosi L; Meroni M; Ubezio P; Fuso Nerini I; Minoli L; Porcu L; Panini N; Colombo M; Blouw B; Kang DW; Davoli E; Zucchetti M; D'Incalci M; Frapolli R
J Exp Clin Cancer Res; 2021 Sep; 40(1):286. PubMed ID: 34507591
[TBL] [Abstract][Full Text] [Related]
2. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Infante JR; Korn RL; Rosen LS; LoRusso P; Dychter SS; Zhu J; Maneval DC; Jiang P; Shepard HM; Frost G; Von Hoff DD; Borad MJ; Ramanathan RK
Br J Cancer; 2018 Jan; 118(2):153-161. PubMed ID: 28949957
[TBL] [Abstract][Full Text] [Related]
7. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.
Brundel DH; Feeney OM; Nowell CJ; Suys EJ; Gracia G; Kaminskas LM; McIntosh MM; Kang DW; Porter CJ
Nanomedicine (Lond); 2021 Feb; 16(4):275-292. PubMed ID: 33560142
[No Abstract] [Full Text] [Related]
8. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.
Li X; Shepard HM; Cowell JA; Zhao C; Osgood RJ; Rosengren S; Blouw B; Garrovillo SA; Pagel MD; Whatcott CJ; Han H; Von Hoff DD; Taverna DM; LaBarre MJ; Maneval DC; Thompson CB
Clin Cancer Res; 2018 Oct; 24(19):4798-4807. PubMed ID: 30084839
[No Abstract] [Full Text] [Related]
9. Effective targeting of the tumor microenvironment for cancer therapy.
Jiang P; Li X; Thompson CB; Huang Z; Araiza F; Osgood R; Wei G; Feldmann M; Frost GI; Shepard HM
Anticancer Res; 2012 Apr; 32(4):1203-12. PubMed ID: 22493350
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.
Kultti A; Zhao C; Singha NC; Zimmerman S; Osgood RJ; Symons R; Jiang P; Li X; Thompson CB; Infante JR; Jacobetz MA; Tuveson DA; Frost GI; Shepard HM; Huang Z
Biomed Res Int; 2014; 2014():817613. PubMed ID: 25147816
[TBL] [Abstract][Full Text] [Related]
12. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy.
Shepard HM
Front Oncol; 2015; 5():192. PubMed ID: 26380222
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance.
Kang L; Lantier L; Kennedy A; Bonner JS; Mayes WH; Bracy DP; Bookbinder LH; Hasty AH; Thompson CB; Wasserman DH
Diabetes; 2013 Jun; 62(6):1888-96. PubMed ID: 23349492
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
[TBL] [Abstract][Full Text] [Related]
15. Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric MRI and MR elastography.
Reeves EL; Li J; Zormpas-Petridis K; Boult JKR; Sullivan J; Cummings C; Blouw B; Kang D; Sinkus R; Bamber JC; Jamin Y; Robinson SP
Mol Oncol; 2023 Jun; 17(6):1076-1092. PubMed ID: 37081807
[TBL] [Abstract][Full Text] [Related]
16. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
19. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
